Clients

Paratek Pharmaceuticals

Company Snapshot: Paratek Pharmaceuticals

PRTK
Last Change Volume High Low

Company Overview

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. The company’s lead product candidate, Omadacycline, is a novel investigational antibiotic with both once-daily intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI), and urinary tract infections (UTI). A modernized tetracycline, omadacycline is specifically designed to overcome tetracycline resistance and exhibits activity across a broad spectrum of bacteria, including Gram-positive, Gram-negative, anaerobes, atypical bacteria, and other drug-resistant strains.

Client News

  1. May 29 2020 Paratek Pharmaceuticals Announces Change to Time of 2020 Annual Meeting of Stockholders
  2. May 28 2020 Paratek Pharmaceuticals to Present at Jefferies 2020 Virtual Healthcare Conference
  3. May 11 2020 Paratek Pharmaceuticals to Present at Bank of America Securities 2020 Health Care Conference
  4. May 11 2020 Paratek Pharmaceuticals Announces First Quarter 2020 Total Revenues of $7.9 Million including NUZYRA® (omadacycline) Net Sales of $7.3 Million